Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | WINREVAIR (sotatercept-csrk) - (CADENCE) | Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Data Released | Subcutaneous | Cardiology |
| Merck & Company Inc. | HRS-5346 | Atherosclerotic cardiovascular disease | Phase 2 | Enrollment Initiation | Oral | Cardiology |
| Merck & Company Inc. | Nebulized ensifentrine | Non-cystic fibrosis bronchiectasis (NCFBE) | Phase 2 | Enrollment Initiation | Inhalation | Respiratory |
| Merck & Company Inc. | Ensifentrine and glycopyrrolate | Chronic obstructive pulmonary disease (COPD) | Phase 2 | Enrollment Conclusion | Ensifentrine inhalation glycopyrrolate inhalation | Respiratory |
| Merck & Company Inc. | Nemtabrutinib - (BELLWAVE-003) | Marginal zone lymphoma | Phase 2 | Ongoing | Oral | Oncology |
| Merck & Company Inc. | Pembrolizumab - (waveLINE-004) | Diffuse large B-cell lymphoma | Phase 2 | Ongoing | Intravenous | Oncology |
| Merck & Company Inc. | Pembrolizumab - (KEYNOTE-667) | Low-risk classic Hodgkin lymphoma (cHL) | Phase 2 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01) | 2L/3L Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
